Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prism Medico and Pharmacy Ltd's Board, in its meeting held on 14 November 2025 (3:30 PM to 6:00 PM), approved the unaudited standalone financial results for the quarter and half year ended 30 September 2025, along with the Limited Review Report by auditors Garg Mendiratta & Associates. For Q2 FY26 (standalone), revenue from operations stood at Rs. 50.23 lakhs with a net loss of Rs. 8.48 lakhs (EPS Rs. -0.0014), compared to a net profit of Rs. 0.94 lakhs in Q2 FY25. In contrast, Q1 FY26 had revenue of Rs. 158.87 lakhs and net profit of Rs. 65.73 lakhs. For H1 FY26, total revenue rose sharply to Rs. 209.10 lakhs (vs Rs. 64.84 lakhs in H1 FY25), with the company turning profitable at Rs. 57.25 lakhs versus a loss of Rs. 4.87 lakhs a year ago (EPS Rs. 0.0094 vs Rs. -0.0008). The company is a single-segment (pharma) entity with paid-up equity capital of Rs. 606.34 lakhs.
Mixed picture for shareholders - H1 FY26 shows a strong year-on-year turnaround with revenue tripling and a swing to profit, but the sharp sequential drop from Q1 to Q2 FY26 and a return to quarterly loss signal volatility and weak business consistency. Stock may react cautiously given the very small absolute scale of operations and uneven quarterly performance.